Bölüm notları
BPC-157 is back in the compounding-policy conversation—but what does HHS's new notice actually change, and what does the human evidence show? In this revisit, John Garrett looks at BPC-157's proposed biology, the three small published human reports, new clinical-trial registry entries, the FDA advisory committee's recommendation, and HHS's October 30 interim enforcement-discretion policy. The published human record remains small and very low certainty.
For BPC-157, the HHS policy identifies the acetate form and specified dosage forms under limited Section 503A circumstances. It is…
Web sitesi: c8cc7b72-7bf7-4a91-b244-e1418d70a491.libsyn.com

